Osteoporosis Medication Denied by Insurance? How to Appeal

Osteoporosis affects more than 10 million Americans and is responsible for 2 million bone fractures each year. Fragility fractures — particularly hip fractures — carry a one-year mortality rate of 20–30%. Effective medications exist to dramatically reduce fracture risk, yet insurance companies routinely deny Prolia (denosumab), Evenity (romosozumab), Reclast (zoledronic acid), and other evidence-based treatments. This guide explains why denials happen and how to fight back.

Common Denial Reasons for Osteoporosis Medications

T-score threshold not met — Insurers typically require a T-score of -2.5 or below (osteoporosis diagnosis) before approving osteoporosis medications. Patients with T-scores between -1.0 and -2.4 (osteopenia) but with significant fracture risk based on FRAX assessment may be denied because they don't meet the raw T-score cutoff.

Prolia (denosumab) Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization denied — Prolia is a RANK ligand inhibitor given by injection every 6 months. Insurers often require documented failure of or contraindication to bisphosphonate therapy (alendronate, risedronate, ibandronate) before approving Prolia. The step therapy requirement may miss patients for whom bisphosphonates are inappropriate.

Evenity (romosozumab) denied — Evenity is a bone-forming agent approved for women with postmenopausal osteoporosis at high risk for fracture. It has strict prior authorization criteria and requires documentation of high fracture risk. Some insurers deny it because of a cardiovascular safety signal in clinical trials.

Reclast (zoledronic acid IV) denied — Annual IV bisphosphonate may be denied when oral bisphosphonates are available, even when patients have GI conditions (esophageal disease, difficulty swallowing) that make oral bisphosphonates inappropriate or dangerous.

DXA scan denied — Coverage for bone density testing (DXA) is subject to frequency limitations. Medicare covers DXA every 2 years for qualifying patients. Denials for DXA scans within the waiting period can delay diagnosis and monitoring.

"Osteopenia does not require treatment" — Insurers sometimes deny medication in patients with osteopenia who have had a fragility fracture, citing the T-score as insufficient. This is clinically wrong when fracture risk is high.

Clinical Frameworks Supporting Your Appeal

NOF/ASBMR Guidelines — The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) and American Society for Bone and Mineral Research (ASBMR) recommend pharmacologic therapy for: (1) postmenopausal women or men ≥50 with T-score ≤-2.5; (2) patients with hip or vertebral fracture regardless of T-score; (3) patients with T-score -1.0 to -2.5 AND 10-year hip fracture probability ≥3% or major osteoporotic fracture probability ≥20% per FRAX.

FRAX Calculation — The Fracture Risk Assessment Tool (FRAX) integrates T-score, age, sex, weight, height, prior fracture, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, and alcohol use to calculate 10-year fracture probability. If your T-score alone is in the osteopenia range but your FRAX score meets treatment thresholds, submit the FRAX calculation and guidelines explicitly. FRAX is available at sheffield.ac.uk/FRAX.

Fragility Fracture = Automatic Indication — A prior hip or vertebral fracture is itself a Class I indication for pharmacologic osteoporosis treatment regardless of T-score. If you have a fragility fracture history, document it. Even a wrist fracture at an older age suggests elevated fracture risk and supports treatment.

Bisphosphonate Contraindications — For patients who cannot take oral bisphosphonates, document the specific contraindication:

• Esophageal stricture, achalasia, or inability to sit upright for 30 minutes (oral alendronate)
• Severe renal impairment (GFR <35 mL/min) — IV zoledronic acid and oral bisphosphonates are contraindicated
• GI intolerance documented on prior trial
• Atypical femur fractures attributed to bisphosphonate use

Glucocorticoid-Induced Osteoporosis (GIOP) — Patients on chronic glucocorticoids (prednisone ≥5 mg/day for ≥3 months) face dramatically accelerated bone loss. ACR GIOP guidelines recommend pharmacologic therapy more aggressively in this population. If your osteoporosis is glucocorticoid-induced, document prednisone dose and duration and cite ACR GIOP guidelines.

Step-by-Step Appeal Strategy

Step 1: Submit the DXA report with T-scores. Include T-scores at lumbar spine, total hip, and femoral neck (the lowest T-score is used for diagnosis). Repeat DXA reports showing progression of bone loss are particularly compelling.

Step 2: Calculate and submit FRAX score. Run the FRAX calculation at the WHO FRAX website and submit the printout with your appeal. If FRAX ≥3% hip or ≥20% major osteoporotic fracture, document this explicitly — it meets BHOF treatment threshold regardless of T-score category.

Step 3: Document bisphosphonate contraindication or failure. For Prolia or Evenity appeals, document each oral bisphosphonate tried, duration, and reason for discontinuation. Include GI records for esophageal conditions, kidney function tests for renal insufficiency, and note any prior atypical fractures attributed to bisphosphonate use.

Step 4: Document fragility fracture history. Submit imaging reports for any hip, vertebral, or low-trauma fractures. Vertebral fractures on imaging studies (compression fractures on spine X-ray or MRI) should be explicitly identified as osteoporotic fragility fractures in physician documentation.

Step 5: Submit a Letter of Medical Necessity from your endocrinologist or prescribing physician. The letter should include: DXA results, FRAX score, fracture history, bisphosphonate trial history, and the specific clinical rationale for the requested agent per BHOF/ASBMR guidelines.

Step 6: File internal appeal then External Independent Review: Complete Guide" class="auto-link">external review. External reviewers apply national guideline standards. Osteoporosis appeals with fracture history or high FRAX scores are frequently overturned.

The Discontinuation Problem: Prolia Rebound

Patients already on Prolia face a unique danger: abrupt discontinuation of Prolia causes a rapid and severe rebound in bone resorption, with documented cases of multiple vertebral fractures within 12–18 months of stopping. If your insurer is denying continued Prolia coverage, this rebound risk must be explicitly communicated in your appeal and is grounds for an expedited review. Prolia discontinuation without a transition to another agent is a patient safety issue.

Fight Back With ClaimBack

Untreated osteoporosis is a preventable cause of disability and death. ClaimBack helps you document your T-scores, FRAX assessment, fracture history, and the BHOF/ASBMR guidelines that support your osteoporosis medication coverage.

Start your osteoporosis appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied